Health Professionals – Melanoma Research Victoria https://melanomaresearchvic.com.au Thu, 21 Jan 2021 04:57:34 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Health Professionals – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 Ideaya Biosciences Begins Trial of IDE196, Xalkori in Uveal Melanoma Patients https://melanomaresearchvic.com.au/ideaya-biosciences-begins-trial-of-ide196-xalkori-in-uveal-melanoma-patients Mon, 25 Jan 2021 04:54:02 +0000 https://melanomaresearchvic.com.au/?p=16261 San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer’s cMET inhibitor crizotinib (Xalkori).

The post Ideaya Biosciences Begins Trial of IDE196, Xalkori in Uveal Melanoma Patients appeared first on Melanoma Research Victoria.

]]>
Source: genomeweb, January 2021

San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer’s cMET inhibitor crizotinib (Xalkori).

Ideaya, which develops precision oncology drugs for patients selected using molecular diagnostics, is evaluating the IDE196-crizotinib combination in metastatic uveal melanoma patients following results from preclinical research demonstrating synergistic activity between the two agents.

Mick O’Quigley, Ideaya’s VP and head of development operations, said in a statement that the company decided to advance the combination to clinical trials based on translational research that included evaluation of cMET expression in samples from metastatic uveal melanoma patients.

READ THE ORIGINAL FULL ARTICLE

The post Ideaya Biosciences Begins Trial of IDE196, Xalkori in Uveal Melanoma Patients appeared first on Melanoma Research Victoria.

]]>
Texas A&M Research Explores How Melanoma Grows And Spreads https://melanomaresearchvic.com.au/texas-am-research-explores-how-melanoma-grows-and-spreads Fri, 22 Jan 2021 06:55:31 +0000 https://melanomaresearchvic.com.au/?p=16255 The first step in treating cancer is understanding how it starts, grows and spreads throughout the body.

The post Texas A&M Research Explores How Melanoma Grows And Spreads appeared first on Melanoma Research Victoria.

]]>
Source: TEXAS A&M TODAY, January 2021

The first step in treating cancer is understanding how it starts, grows and spreads throughout the body.

A relatively new cancer research approach is the study of metabolites, the products of different steps in cancer cell metabolism, and how those substances interact.

To date, research like this has focused mostly on cancerous tissues; however, normal tissues that surround tumors, known as the extratumoral microenvironment (EM), may have conditions favorable for tumor formation and should also be studied.

READ THE ORIGINAL FULL ARTICLE

The post Texas A&M Research Explores How Melanoma Grows And Spreads appeared first on Melanoma Research Victoria.

]]>
Ultraviolet radiation causes rare type of eye cancer https://melanomaresearchvic.com.au/ultraviolet-radiation-causes-rare-type-of-eye-cancer Fri, 22 Jan 2021 06:50:50 +0000 https://melanomaresearchvic.com.au/?p=16253 Ultraviolet radiation can cause a rare type of eye cancer, conjunctival melanoma, according to University of Manchester research funded by Cancer Research UK and others* and published** in Nature Communications today (Monday).

The post Ultraviolet radiation causes rare type of eye cancer appeared first on Melanoma Research Victoria.

]]>
Source: The University of Manchester, January 2021

Ultraviolet radiation can cause a rare type of eye cancer, conjunctival melanoma, according to University of Manchester research funded by Cancer Research UK and others* and published** in Nature Communications today (Monday).

UV radiation is known to be the key environmental cause of melanoma of the skin, but its role in the development of rarer forms of melanoma in the eye was not known.

This new study has revealed strikingly similar genetic changes in conjunctival melanoma to that of cutaneous (skin) melanoma caused by ultraviolet (UV) radiation.

READ THE ORIGINAL FULL ARTICLE

The post Ultraviolet radiation causes rare type of eye cancer appeared first on Melanoma Research Victoria.

]]>
Advanced humanized mouse model helps better understand immunotherapy resistance in melanoma https://melanomaresearchvic.com.au/advanced-humanized-mouse-model-helps-better-understand-immunotherapy-resistance-in-melanoma Fri, 22 Jan 2021 06:47:56 +0000 https://melanomaresearchvic.com.au/?p=16251 Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma.

The post Advanced humanized mouse model helps better understand immunotherapy resistance in melanoma appeared first on Melanoma Research Victoria.

]]>
Source: News Medical Life Sciences, January 2021

Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma.

It has revealed a central role for mast cells. These findings were published today in the journal Nature Communications.

Checkpoint inhibitors revolutionized therapeutic options for advanced melanoma.

READ THE ORIGINAL FULL ARTICLE

The post Advanced humanized mouse model helps better understand immunotherapy resistance in melanoma appeared first on Melanoma Research Victoria.

]]>
New humanized mouse model provides insight into immunotherapy resistance https://melanomaresearchvic.com.au/new-humanized-mouse-model-provides-insight-into-immunotherapy-resistance Thu, 21 Jan 2021 06:37:07 +0000 https://melanomaresearchvic.com.au/?p=16247 Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma.

The post New humanized mouse model provides insight into immunotherapy resistance appeared first on Melanoma Research Victoria.

]]>
Source: EurekAlert!, January 2021

Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma.

It has revealed a central role for mast cells.

These findings were published today in the journal Nature Communications.

READ THE ORIGINAL FULL ARTICLE

The post New humanized mouse model provides insight into immunotherapy resistance appeared first on Melanoma Research Victoria.

]]>
Regression may predict good prognosis in stage 1 and 2 cutaneous melanomas https://melanomaresearchvic.com.au/regression-may-predict-good-prognosis-in-stage-1-and-2-cutaneous-melanomas Thu, 21 Jan 2021 06:31:34 +0000 https://melanomaresearchvic.com.au/?p=16245 Disease regression was associated with improved recurrence-free survival and overall survival among certain patients with stage 1 and 2 cutaneous melanomas, according to a study.

The post Regression may predict good prognosis in stage 1 and 2 cutaneous melanomas appeared first on Melanoma Research Victoria.

]]>
Source: Healio, January 2021

Disease regression was associated with improved recurrence-free survival and overall survival among certain patients with stage 1 and 2 cutaneous melanomas, according to a study.

“Although regression is commonly observed in cutaneous melanoma, it is uncertain whether it is associated with patient prognosis,” Mary-Ann El Sharouni, MD, of the Melanoma Institute Australia at The University of Sydney and the department of dermatology at University Medical Center Utrecht at Utrecht University, the Netherlands, and colleagues wrote.

In the cohort study involving 17,271 Dutch patients and 4,980 Australian patients with stage 1 and 2 primary cutaneous melanomas, the researchers aimed to determine whether histologically confirmed regression was associated with better or worse survival.

READ THE ORIGINAL FULL ARTICLE

The post Regression may predict good prognosis in stage 1 and 2 cutaneous melanomas appeared first on Melanoma Research Victoria.

]]>
Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma https://melanomaresearchvic.com.au/philogen-announces-the-completion-of-a-second-interim-analysis-of-its-phase-iii-clinical-program-with-nidlegy-for-the-treatment-of-melanoma Wed, 20 Jan 2021 06:22:47 +0000 https://melanomaresearchvic.com.au/?p=16241 Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce that 50% of the expected events for the primary outcome analysis of the PIVOTAL study were reached in December 2020.

The post Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: PR Newswire, January 2021

hilogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce that 50% of the expected events for the primary outcome analysis of the PIVOTAL study were reached in December 2020.

In this phase III clinical trial, the effect of Nidlegy™ is evaluated in melanoma patients with locally advanced, fully resectable metastatic cancer, and at the time of the second interim analysis, had already recruited 149 out of the anticipated 214 patients (one additional patient was enrolled recently).

As a consequence, the second interim data analysis foreseen by the clinical protocol was carried out and submitted to the Data and Safety Monitoring Board of the study for their consideration.

READ THE ORIGINAL FULL ARTICLE

The post Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma appeared first on Melanoma Research Victoria.

]]>
World first melanoma success in Australia prompts new trial https://melanomaresearchvic.com.au/world-first-melanoma-success-in-australia-prompts-new-trial Wed, 20 Jan 2021 06:04:55 +0000 https://melanomaresearchvic.com.au/?p=16239 A Sydney man who was seriously ill with advanced melanoma has made a remarkable recovery after receiving a drug reserved for breast and ovarian cancer.

The post World first melanoma success in Australia prompts new trial appeared first on Melanoma Research Victoria.

]]>
Source: 9NEWS, January 2021

A Sydney man who was seriously ill with advanced melanoma has made a remarkable recovery after receiving a drug reserved for breast and ovarian cancer.
Charles Hanna had exhausted all treatments for his cancer, but tumours in his upper abdomen have now vanished.
His world-first case has prompted the Melanoma Institute to run a new clinical trial.

READ THE ORIGINAL FULL ARTICLE

 

The post World first melanoma success in Australia prompts new trial appeared first on Melanoma Research Victoria.

]]>
Sydney man recovers from advanced melanoma in unconventional treatment https://melanomaresearchvic.com.au/sydney-man-recovers-from-advanced-melanoma-in-unconventional-treatment Tue, 19 Jan 2021 05:28:50 +0000 https://melanomaresearchvic.com.au/?p=16233 A Sydney man has recovered from advanced melanoma thanks to a drug usually used for breast and ovarian cancer, prompting the Melanoma Institute to run a new clinical trial.

The post Sydney man recovers from advanced melanoma in unconventional treatment appeared first on Melanoma Research Victoria.

]]>
Source: 9NEWS, January 2021

A Sydney man has recovered from advanced melanoma thanks to a drug usually used for breast and ovarian cancer, prompting the Melanoma Institute to run a new clinical trial.

SEE THE ORIGINAL FULL UPDATE

 

The post Sydney man recovers from advanced melanoma in unconventional treatment appeared first on Melanoma Research Victoria.

]]>
Study reveals significant role of ADAMTS1 protein in uveal melanoma https://melanomaresearchvic.com.au/study-reveals-significant-role-of-adamts1-protein-in-uveal-melanoma Tue, 19 Jan 2021 04:58:37 +0000 https://melanomaresearchvic.com.au/?p=16229 Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.

The post Study reveals significant role of ADAMTS1 protein in uveal melanoma appeared first on Melanoma Research Victoria.

]]>
Source: News Medical Life Sciences, January 2021

Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.

tumors are composed not only of a mass of cells that grow uncontrollably but also of the environment they create during their growth—together creating what is known as the ‘tumor microenvironment’.

Within this environment, there are proteins that remodel it, known as extracellular proteases, which are capable of inhibiting or contributing to tumor growth and metastasis.

READ THE ORIGINAL FULL ARTICLE

The post Study reveals significant role of ADAMTS1 protein in uveal melanoma appeared first on Melanoma Research Victoria.

]]>